Table 1.
Treatment | Donor | HDR (%) | mutEJ (%) | |
---|---|---|---|---|
Nick | — | SSO | 0.05–0.2 | 0.01–0.1 |
siBRCA2 | SSO | 2–5 | 0.05–0.5 | |
— | dsDNA plasmid | 0.2–0.5 | 0.01–0.1 | |
siBRCA2 | dsDNA plasmid | 0.010.1 | 0.3–0.8 | |
DSB | — | SSO | 2–4 | 1–3 |
siBRCA2 | SSO | 2–4 | 1–3 | |
— | dsDNA plasmid | 1–3 | 1–3 | |
siBRCA2 | dsDNA plasmid | 0.2–0.5 | 1–2 |
Frequencies were determined by scoring the fraction of GFP+ or mCherry+ cells among BFP+ cells in 293T TL reporter cells. As described in the text, the frequency of mutEJ is determined by a frame-shift assay, based on the fraction of mCherry+ cells, and the actual frequency of mutEJ is predicted to be at threefold higher than the value shown.